2026-06-07T06:20:38Zhttps://docta.ucm.es/rest/oai/requestoai:docta.ucm.es:20.500.14352/717572023-08-26T05:27:31Zcom_20.500.14352_14col_20.500.14352_15
Bikdeli, Behnood
Jiménez, David
Demelo Rodríguez, Pablo
Galeano Valle, Francisco
Porras, José Antonio
Barba, Raquel
Ay, Cihan
Malý, Radovan
Braester, Andrei
Imbalzano, Egidio
Rosa, Vladimir
Lecumberri, Ramón
Siniscalchi, Carmine
Fidalgo, Ángeles
Ortiz, Salvador
Monreal, Manuel
2023-06-22T10:50:17Z
2023-06-22T10:50:17Z
2022-01-18
1999-4915
10.3390/v14020178
https://hdl.handle.net/20.500.14352/71757
https://doi.org/10.3390/v14020178
https://www.mdpi.com/1999-4915/14/2/178/htm
Background: Venous thromboembolism (VTE)—including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)—may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. Methods: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) platform, patients with VTE 4–30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018–2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. Results: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7–94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07–47.13). The site of thrombosis, accompanying thrombocytopenia, and 14-day mortality rates were not significantly different for patients with VTE after mRNA-based vaccination, compared with historical controls. Conclusions: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes.
eng
https://creativecommons.org/licenses/by/3.0/es/
open access
Atribución 3.0 España
Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry
journal article